Norden Group LLC Grows Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Norden Group LLC boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 207.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,014 shares of the company’s stock after acquiring an additional 3,385 shares during the period. Norden Group LLC’s holdings in Medpace were worth $1,537,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Riverbridge Partners LLC lifted its holdings in shares of Medpace by 7.1% during the 4th quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock valued at $199,975,000 after purchasing an additional 43,197 shares during the last quarter. Invesco Ltd. increased its position in Medpace by 67.6% during the 3rd quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock valued at $148,159,000 after buying an additional 246,775 shares in the last quarter. Wellington Management Group LLP raised its stake in Medpace by 312.6% in the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock valued at $102,013,000 after buying an additional 319,210 shares during the last quarter. Northern Trust Corp boosted its holdings in Medpace by 4.0% in the third quarter. Northern Trust Corp now owns 241,202 shares of the company’s stock worth $58,402,000 after acquiring an additional 9,192 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Medpace by 55.7% during the third quarter. AQR Capital Management LLC now owns 183,310 shares of the company’s stock worth $44,385,000 after acquiring an additional 65,614 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Guggenheim increased their price objective on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and raised their price target for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 price objective on the stock. Robert W. Baird raised their target price on Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Finally, StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Stock Down 2.0 %

Shares of NASDAQ:MEDP traded down $7.96 during midday trading on Tuesday, reaching $392.25. The company’s stock had a trading volume of 94,156 shares, compared to its average volume of 248,741. The stock has a fifty day moving average of $398.00 and a 200 day moving average of $327.40. Medpace Holdings, Inc. has a twelve month low of $197.39 and a twelve month high of $421.00. The firm has a market capitalization of $12.15 billion, a PE ratio of 40.57, a P/E/G ratio of 1.97 and a beta of 1.38.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. The company had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The firm’s revenue for the quarter was up 17.7% compared to the same quarter last year. During the same period last year, the firm earned $2.27 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the sale, the chief executive officer now owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, VP Susan E. Burwig sold 102 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares in the company, valued at $6,117,943. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the transaction, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The disclosure for this sale can be found here. Insiders sold a total of 189,340 shares of company stock valued at $76,651,647 in the last three months. 20.30% of the stock is currently owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.